Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 26;3(6):862-868.
doi: 10.1182/bloodadvances.2018025890.

Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years

Polina Stepensky  1 , Sigal Grisariu  1 , Batia Avni  1 , Irina Zaidman  1 , Bella Shadur  1   2   3 , Orly Elpeleg  4 , Mehtap Sirin  5 , Manfred Hoenig  5 , Catharina Schuetz  5 , Ingrid Furlan  5 , Meinrad Beer  6 , Stephanie von Harsdorf  7 , Donald Bunjes  7 , Klaus-Michael Debatin  5 , Ansgar S Schulz  5
Affiliations

Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years

Polina Stepensky et al. Blood Adv. .

Abstract

Osteopetrosis (OP) is a rare disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available in the infantile "malignant" form of OP. Improved clinical and genetic diagnosis of OP has seen the emergence of a cohort of patients with less severe and heterogeneous clinical presentations. This intermediate form of OP does not call for urgent intervention, but patients accumulate debilitating skeletal complications over years and decades, which are severe enough to require curative treatment and may also require intermittent transfusion of blood products. Here we present data from 7 patients with intermediate OP caused by mutations in TCIRG1 (n = 2), CLCN7 (n = 2), RANK (n = 1), SNX10 (n = 1), and CA2 (n = 1), who were transplanted between the ages of 5 to 30 years (mean, 15; median, 12). Donors were matched siblings or family (n = 4), matched unrelated (n = 2), or HLA haploidentical family donors (n = 1). Conditioning was fludarabine and treosulfan based. All 6 patients transplanted from matched donors are currently alive with a follow-up period between 1 and 8 years at time of publication (median, 4 years) and have demonstrated a significant improvement in symptoms and quality of life. Patients with intermediate OP should be considered for HSCT.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Baseline and follow-up plain radiography of the left lower extremity (femur) of patient 3. (A) Before HSCT, highly increased bone density with significantly diminished radiograph transparency, “ballooning,” especially of the distal femoral diaphysis, and meta/epiphysis. Transversal intraosseous dense horizontal lines are seen. (B) About 4 years after HSCT regression/normalization of bone density, however, decreased cortical lining and even increased osseous “ballooning” is seen. (C) About 8 years after HSCT, remodeling of bone size and complete normalization of cortical thickness is seen.
See this image and copyright information in PMC

References

    1. Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-536. - PubMed
    1. Fasth A, Porras O. Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant. 1999;3(suppl 1):102-107. - PubMed
    1. Bliznetz EA, Tverskaya SM, Zinchenko RA, et al. Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect. Eur J Hum Genet. 2009;17(5):664-672. - PMC - PubMed
    1. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-2849. - PubMed
    1. Whyte MP. Sclerosing bone disorders. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. New York: Lippincott Willians & Wilkins; 1999:367-383.

Publication types